drugset / Trial / NCT01821001

Vaginal Bromocriptine for Treatment of Adenomyosis

NCT01821001

Phase 1 Completed 1 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

Adenomyosis is a rare non-malignant disease of the uterus that causes significant symptoms including heavy menstrual bleeding and pelvic pain. The only widely accepted treatment for adenomyosis is hysterectomy. The investigators will use a dopamine agonist, bromocriptine, as a therapy based on animal models of the disease and our prior clinical research to observe any objective improvement in the extent of the disease using Magnetic Resonance Imaging (MRI)and standard measurements for other gynecologic diseases to measure symptomatology.

Timeline

Start
2013-03
Primary completion
2017-09
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bromocriptine Small molecule 2.5 mg Other

Indications